EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Nurix Therapeutics, Inc. (NRIX) had EBIT Margin of -340.67% for the most recently reported fiscal quarter, ending 2025-02-28.
| Income Statement Financials | |
$18.45M |
|
$-56.35M |
|
-- |
|
$18.45M |
|
$81.32M |
|
$-62.86M |
|
$6.51M |
|
$-56.35M |
|
$-56.35M |
|
$-56.35M |
|
$-56.35M |
|
$-56.35M |
|
$-56.35M |
|
$-62.86M |
|
$-58.74M |
|
83.56M |
|
83.56M |
|
$-0.67 |
|
$-0.67 |
|
| Balance Sheet Financials | |
$563.70M |
|
$18.45M |
|
$51.34M |
|
$615.04M |
|
$89.99M |
|
-- |
|
$44.14M |
|
$134.13M |
|
$480.92M |
|
$480.92M |
|
$480.92M |
|
76.23M |
|
| Cash Flow Statement Financials | |
$-61.09M |
|
$25.53M |
|
$1.47M |
|
$110.90M |
|
$76.82M |
|
$-34.08M |
|
$8.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.26 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-340.67% |
|
|
EBIT Margin |
-340.67% |
-- |
|
-305.38% |
|
-305.38% |
|
$-64.57M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-11.72% |
|
-11.72% |
|
-9.16% |
|
-11.72% |
|
$6.31 |
|
$-0.77 |
|
$-0.73 |
|